| THOMAS JEFFERSON UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120100116 | NEURON GENERATION, REGENERATION AND PROTECTION - The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress. | 04-26-2012 |
| 20120064039 | Use of Guanylyl Cyclase C Agonists to Suppress Appetite - Compositions comprising a guanylyl cyclase C agonist formulated for sustained specific release of an amount effective to suppress appetite when administered orally to an individual are disclosed. Compositions comprising a guanylyl cyclase C agonist formulated for intravenous delivery in an amount effective to suppress appetite when administered intravenously to an individual are also disclosed. Methods of suppressing appetite in an individual are disclosed. | 03-15-2012 |
| 20120015368 | BIOMARKERS FOR EARLY DIAGNOSIS OF SYSTEMIC TISSUE FIBROSIS - Embodiments of the invention provides methods, devices and kits for determining the likelihood of an individual having an active fibrotic condition and/or early diagnosis, and subsequently prognosis evaluation of an individual having an active fibrotic condition such as systemic sclerosis (SSc) and/or nephrogenic systemic fibrosis (NSF) by measuring the levels of several biomarkers: α-enolase (ENO1), reticulocalbin 3 (RCN-3), alpha smooth muscle actin (α-SMA), reticulocalbin 1 (RCN-1) and pigment epithelium-derived factor (PEDF) in the individual. | 01-19-2012 |
| 20110260726 | PHASE LABELING USING SENSITIVITY ENCODING: DATA ACQUISITION AND IMAGE RECONSTRUCTION FOR GEOMETRIC DISTORTION CORRECTION IN EPI - A phase labeling using sensitivity encoding system and method for correcting geometric distortion caused by magnetic field inhomogeneity in echo planar imaging (EPI) uses local phase shifts derived directly from the EPI measurement itself, without the need for extra field map scans or coil sensitivity maps. The system and method employs parallel imaging and k-space trajectory modification to produce multiple images from a single acquisition. The EPI measurement is also used to derive sensitivity maps for parallel imaging reconstruction. The derived phase shifts are retrospectively applied to the EPI measurement for correction of geometric distortion in the measurement itself. | 10-27-2011 |
| 20110250228 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. | 10-13-2011 |
| 20110244570 | VOLUME EXCLUSION AGENT TO ENHANCE FORMATION OF EXTRACELLULAR MATRIX - A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks. | 10-06-2011 |
| 20110206736 | Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same - Nucleic acid molecules comprising a nucleotide sequence that encodes a chimeric protein are disclosed. The chimeric proteins comprise at least one epitope of a mucosally restricted antigen, at least one CD4+ helper epitope, and, optionally, a secretion sequence. Chimeric proteins that comprise at least one epitope of a mucosally restricted antigen, at least one CD4+helper epitope and, optionally a secretion sequence are also disclosed. Compositions including pharmaceutical compositions and injectables comprising nucleic acid molecule and proteins are disclosed. Methods of treating individuals diagnosed with cancer of a mucosal tissue and methods of preventing cancer of a mucosal tissue are disclosed. | 08-25-2011 |
| 20110195415 | GUANYLYL CYCLASE C QRT-PCR - Methods, kits, compositions and systems for detecting the level of GCC encoding mRNA present in a sample using quantitative (q) RT-PCR are disclosed. The methods, kits, compositions and systems may be used to detect metastasis in patients diagnosed with primary colorectal, gastric or esophageal cancer, to predict the risk of occurrence of relapse in patients diagnosed with primary colorectal, gastric or esophageal cancer, and to diagnose Barrett's esophagus. | 08-11-2011 |
| 20110184019 | Long chain N-Alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 07-28-2011 |
| 20110104050 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed. | 05-05-2011 |
| 20110064764 | Attenuated Live Triple G Protein Recombinant Rabies Virus Vaccine for Pre- and Post-Exposure Prophylaxis of Rabies - The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues. | 03-17-2011 |
| 20110008344 | FUSION PARTNER CELL LINE FOR PREPARATION OF HYBRID CELLS EXPRESSING HUMAN ANTIBODIES - This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies. | 01-13-2011 |
| 20110002937 | METHOD OF MAKING HYBRID CELLS THAT EXPRESS USEFUL ANTIBODIES - This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention. | 01-06-2011 |
| 20100297264 | BOWEL PURGATIVE AND USES THEREOF - The present invention is directed to a dry composition for admixture with water for oral administration to a mammal and methods of using the composition for cleansing the bowel of a mammal in need thereof. | 11-25-2010 |
| 20100285480 | TCL-1 GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS - The present invention relates to nucleotide sequences of TCL-1 genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation. The present invention further relates to the use of TCL-1 genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with chromosomal abnormalities. | 11-11-2010 |
| 20100272711 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES - The present invention is directed to a pharmaceutical composition, and methods of use thereof, comprising at least one agent which target multiple adenosine receptors (AR) simultaneously in a stoichiometric relationship (i.e. each AR receptor is targeted to an equal extent). Aspects of the present invention relate to pharmaceutical compositions, and uses thereof, comprising at least one agent which co-activates an A | 10-28-2010 |
| 20100247560 | MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF - Modified polypeptides based on the | 09-30-2010 |
| 20100234241 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 09-16-2010 |
| 20100222555 | Monoclonal antibodies that neutralize botulinum neurotoxin - This invention provides antibodies that specifically bind to botulinum neurotoxin type A (BoNT/A) and/or botulinum neurotoxin type B (BoNT/B) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. Also included in the invention are diagnostic and therapeutic assays directed to botulinum neurotoxins. | 09-02-2010 |
| 20100221290 | MIXED HAPTENIZED TUMOR CELLS AND EXTRACTS AND METHODS OF TREATING OR SCREENING FOR CANCER - This invention relates to compositions comprising multi-haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such multi-haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma and ovarian adenocarcinoma cells are multi-haptenized, wherein the tumor cells are differentially haptenized either with a dinitrophenyl group coupled to s-amino groups, or with a sulfanilic acid group coupled to aromatic side chains of histidine and tyrosine. A method of SA-haptenization is also provided. | 09-02-2010 |
| 20100203544 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 08-12-2010 |
| 20100192235 | HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA MODELED IN MOUSE BY TARGETED TCL1 EXPRESSION - Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic leukemia. | 07-29-2010 |
| 20100190840 | TISSUE SPECIFIC GENE THERAPY TREATMENT - The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca | 07-29-2010 |
| 20100173319 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND THERAPY - The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases. | 07-08-2010 |
| 20100137365 | Long chain N-alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 06-03-2010 |
| 20100056445 | ADIPONECTIN FOR THE TREATMENT AND DIAGNOSIS OF ALBUMINURIA - Disclosed are methods relating to the treatment and/or prevention of kidney disorders, especially kidney disorders characterized by or involving albuminuria. Methods described include the administration of an adiponectin polypeptide or a nucleic acid encoding such a polypeptide to treat or prevent the development of albuminuria. Also described are methods in which adiponectin is measured as a predictor of a subject's likelihood of having or developing a kidney disorder characterized by or involving albuminuria. Also described are methods of treating or preventing a kidney disorder involving administering an AMPK agonist and/or an inhibitor of Nox4 activity. | 03-04-2010 |
| 20100048479 | ADRENAL GRK2 ACTIVITY AS A THERAPEUTIC TARGET FOR HEART FAILURE - The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving the cardiac adrenergic/inotropic reserve and overall contractile function. | 02-25-2010 |
| 20100047798 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME - The present invention relates to methods for identify subjects for responsiveness to adenosine agonist treatment. Another aspect of the present invention relates to methods to predict a relative infarct size in response to ischemia reperfusion injury. In particular, the present invention relates to methods for to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences such as mutations and/or polymorphisms in the human A1 adenosine receptor (A1-AR) gene that alters the stability of the A1-AR mRNA. Other aspect of the present invention relates to methods to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences, such as mutations and/or polymorphisms in the human A3 adenosine receptor (A3-AR) gene that alters the A3-AR protein function. Other aspect of the present invention also relate to kits and assays to detect sequence differences in the human A1 adenosine receptor (A1-AR) gene and/or A3 adenosine receptor (A3-AR) gene. | 02-25-2010 |
| 20100029570 | PEPTIDE AND TREATMENT FOR HIV-1 INFECTION - A compound of the formula X | 02-04-2010 |
| 20100029568 | TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY - The invention provides compositions and methods for the treatment of HIV infection, inhibition against drug-resistant strains of HIV-1 and methods of enhancing the anti-HIV potency of peptide inhibitors against drug-resistant strains of HIV-1. In particular, oligomeric C-peptide inhibitors for inhibiting HIV entry into host cells are disclosed. | 02-04-2010 |
| 20100021915 | HIGH THROUGHPUT DNA SEQUENCING METHOD AND APPARATUS - The present invention relates to a method for high throughput nucleic acid sequencing using a multi-bead flow cell and pyrophosphate sequencing, a sequencer capable of performing this method, and a kit of the pyrophosphate sequencing reagents. | 01-28-2010 |
| 20100008964 | ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. | 01-14-2010 |
| 20100003269 | METHODS AND USES OF CAULIFLOWER AND COLLARD FOR RECOMBINANT PROTEIN PRODUCTION - The present invention relates to a method for the generation of transgenic | 01-07-2010 |
| 20090299357 | CRYONEEDLE AND CRYOTHERAPHY SYSTEM - A device and system for cryogenically treating tissue having an external cryoneedle including an outer housing having a proximal end, a proximal portion, a distal portion and a distal end. The proximal portion of the outer housing is coated with a first material and the distal portion of the outer housing is coated with a second material. The distal end is sealed with a third material. The first material has different temperature conductive properties than the second and third materials. An internal cryoneedle having a first and second end is axially disposed within the external cryoneedle. The first end of the internal cryoneedle is in communication with the sealed distal end of the external cryoneedle and the second end of the internal cryoneedle being in fluid communication with a cryogen source. | 12-03-2009 |
| 20090123533 | Compositions and methods for cancer diagnosis and therapy - The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases. | 05-14-2009 |
| 20090053248 | Compositions and methods for transepithelial molecular transport - The invention relates to fragments of | 02-26-2009 |
| 20090035347 | ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. | 02-05-2009 |
| 20090023977 | Method of Treatment to Improve Concentration and/or Memory in a Subject in Need Thereof - The present invention is directed to a method of treatment to improve at least one of concentration, memory, cognitive performance, and stress-relief in a subject in need thereof by controlled administration of synchronized flashes of light and pulsed tones. | 01-22-2009 |
| 20080286799 | METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING COLORECTAL TUMORS... - In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed. | 11-20-2008 |
| 20080280829 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing metabolic bone diseases and disorders by inhibition of Lp-PLA | 11-13-2008 |
| 20080279846 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia. | 11-13-2008 |
| 20080256650 | Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression - Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic leukemia. | 10-16-2008 |
